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The term “thyrogastric syndrome” defines the association between autoimmune 
thyroid disease and chronic autoimmune gastritis (CAG), and it was first described 
in the early 1960s. More recently, this association has been included in polyglan-
dular autoimmune syndrome type IIIb, in which autoimmune thyroiditis represents 
the pivotal disorder. Hashimoto’s thyroiditis (HT) is the most frequent autoimmune 
disease, and it has been reported to be associated with gastric disorders in 10–40% 
of patients while about 40% of patients with autoimmune gastritis also present HT. 
Some intriguing similarities have been described about the pathogenic mechanism of 
these two disorders, involving a complex interaction among genetic, embryological, 
immunologic, and environmental factors. CAG is characterized by a partial or total 
disappearance of parietal cells implying the impairment of both hydrochloric acid and 
intrinsic factor production. The clinical outcome of this gastric damage is the occur-
rence of a hypochlorhydric-dependent iron-deficient anemia, followed by pernicious 
anemia concomitant with the progression to a severe gastric atrophy. Malabsorption 
of levothyroxine may occur as well. We have briefly summarized in this minireview the 
most recent achievements on this peculiar association of diseases that, in the last 
years, have been increasingly diagnosed.
Keywords: thyroiditis, polyglandular autoimmune syndrome, thyroxine malabsorption, gastric atrophy, pernicious 
anemia, Helicobacter pylori infection, cellular immunity
inTRODUCTiOn
The thyrogastric syndrome was initially described in the early 1960s and initially characterized 
by the presence of thyroid autoantibodies in patients with pernicious anemia, the latter being 
used as synonymous for atrophic gastritis (1). More recently, the autoimmune gastritis has been 
better characterized classifying chronic atrophic gastritis, with or without the PA, based on the 
histological evaluation and the presence of serum parietal cell (PCA) and/or intrinsic factor 
(IFA) autoantibodies (2, 3). Based on these criteria, the association between autoimmune thyroid 
disorders and chronic autoimmune gastritis (CAG) has also been reassessed (4, 5) and nowadays 
is included in the adult form of polyglandular autoimmune syndrome (PAS), characterized by 
two or more endocrine and non-endocrine autoimmune disorders (6). In particular, Betterle 
and colleagues have proposed the inclusion of thyrogastric syndrome in the PAS Type 3b, in 
which Hashimoto’s thyroiditis (HT) occurs also associated with non-endocrine autoimmune 
gastrointestinal disorders and where it plays a pivotal role (7, 8). This is in keeping with the 
TAble 1 | Shared characteristics between thyroid and stomach.
Embryological origin •	 Primitive gut for both thyroid and stomach
Cell features •	 Presence of cells polarity
•	 Cells characterized by apical microvilli
Biochemical features •	 Presence of Na+/I− symporter (sodium-iodide 
symporter)
•	 Presence of peroxidase isoenzymes (TPO and GPO)
Function •	 Ability to concentrate iodine
•	 Presence of antioxidative activities
•	 Secretion of mucinous glycoproteins: thyroglobulin 
and mucine
Pathogenesis •	 Cellular immune involvement
•	 Similarity of autoaggressive processes
•	 Mechanisms of cellular damage
•	 Expression of autoantigens and related cross-reacting 
autoantibodies
Pathology •	 Clinically related autoimmune disorders
•	 Peculiar associative clinical features
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evidence that chronic autoimmune thyroiditis represents the 
more prevalent autoimmune disorder worldwide making the 
frequency of thyrogastric syndrome quite high (4). This notion 
is supported by the high percentage (12–40%) of positivity of 
PCA in adult patients with HT (9) which, in turn, is present 
in approximately 40% of patients with atrophic gastritis (10). 
Besides the fact that the thyroid and the stomach share some 
embryological and biochemical features (11), some intriguing 
similarities have been observed even in the putative pathogenic 
mechanisms, which characterize the thyrogastric syndrome 
(12). Furthermore, some specific clinical features characterize 
or lead to the suspicion of the coexistence of both thyroid and 
gastric autoimmune (13, 14) disorders. These similar peculiar 
features will be briefly described in this minireview.
THYROiD AnD STOMACH: 
eMbRYOlOGiC DeRivATiOn AnD ROle 
of na+/i− SYMPORTeR
The thyroid gland and stomach, despite the different localization 
and function, share some similar morphologic and functional 
characteristics, likely due to their common embryologic origin 
(11). In fact, the thyroid gland develops from the primitive gut 
and therefore thyroid follicular share with parietal cells the same 
endodermal origin. Also, both these cells are polarized and are 
characterized by the presence of apical microvilli housing enzy-
matic activities.
Furthermore, gastric mucosal and thyroid follicular cells 
both show the ability to concentrate and transport iodine across 
the cell membrane (15). This process is mediated by the Na+/I−  
symporter (15) and involves similar enzymes with an efficient 
peroxidase activity (12) (Table  1). Furthermore, besides its 
essential role for the synthesis of thyroid hormones, iodine 
regulates the proliferation of gastric mucosal cells (16). In fact, 
in the presence of gastric peroxidase, iodine acts as an electron 
donor and participates in the removal of free oxygen radicals, 
thus playing an antioxidant action (17). These effects may explain 
the regulatory role of iodine in the proliferation of mucosal cells 
and its protective role against gastric carcinogenesis (11, 16). 
This hypothesis has been confirmed by the reported link among 
iodine deficiency, goiter, and increased risk of developing gastric 
cancer (18).
CHROniC AUTOiMMUne/HASHiMOTO’S 
THYROiDiTiS AnD CAG
Chronic lymphocytic thyroiditis is the most frequent autoim-
mune disorder and represents the prototype of organ-specific 
autoimmunity (19). Its prevalence, despite some difference of 
sex, age, race, and iodine intake, reaches about 5% in the general 
population (20). Much less frequent is the chronic autoimmune 
atrophic gastritis (type A gastritis or body/fundus gastritis), which 
represents only some 5% of the whole spectrum of chronic gastritis 
and must be differentiated from the one associated with chronic 
Helicobacter pylori (Hp) infection (type B gastritis or antral gastri-
tis) (21, 22). HT is characterized by diffuse inflammatory changes 
with lymphocytic infiltration of the thyroid gland, leading to the 
destruction of the thyroid epithelial cells with subsequent fibrosis 
(23). Similarly, autoimmune gastritis is a chronic inflammatory 
disease involving gastric body and fundus, with the progressive 
reduction and/or disappearance of the native gastric glands that 
are sometimes replaced by intestinal or pyloric epithelium (meta-
plasia) (3). The natural history of HT is the progressive reduction 
of thyroid function till overt hypothyroidism (24) with a rate of 
progression of 2–4% per year (23), while that of gastric atrophy 
features the progressive reduction, till disappearance, of parietal 
cells, leading to reduced or absent acid production (3, 22). These 
alterations interfere with absorption of essential nutrients leading, 
at first, to iron-deficient anemia, followed by PA if the self-injurious 
process involves the IFA (13). Increased risk of developing neu-
roendocrine tumors and gastric adenocarcinoma is also associated 
with the severity of damage of gastric mucosa (22).
Pathogenesis
Both these autoimmune disorders are characterized by a complex 
interaction between genetic susceptibility and environmental fac-
tors that results in the loss of immune tolerance to self-antigens 
and in the development of autoimmune diseases. The loss of 
immune tolerance may involve alteration both in the central toler-
ance with reactive T cells escaped from intrathymic deletion and 
in the peripheral tolerance as in the case of defective T regulatory 
lymphocytes (25, 26). Genetic susceptibility has been confirmed 
for both diseases since their incidence is higher among identical 
twins and first-degree relatives as well as their presence may be 
observed in association with further autoimmune disorders (6, 7, 
20, 26). Both of these disorders show a definite association with 
different HLA aplotypes; in HT, it has also been proven that the 
involvement of many other immunoregulatory genes (27), while 
this issue has not been elucidated in the pathogenesis of human 
autoimmune gastritis (26).
Several environmental factors seem to be involved in the 
pathogenesis of HT (excessive iodine intake, selenium deficiency, 
and specific drugs use), while very weak evidence supports a role 
for infectious agents as trigger for this disease (hepatitis C virus, 
HHV-6, and Yersinia) (27). The role of environmental factors 
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in triggering autoimmune gastritis has been more studied and 
a stronger link between H. pylori infection and CAG has been 
detected, despite not sufficient to establish a causative relation-
ship between these two diseases (21). H. pylori infection affects 
approximately 50% of the world population and is in turn the most 
common cause of chronic gastritis. At first, the H. pylori infection 
involves the gastric antrum, but in some patients it may extend 
into the gastric body (pangastritis) and, in genetically predisposed 
individuals, it may be a trigger for autoimmune atrophic gastritis, 
being this hypothesis still debated (3, 28, 29). The pathogenic 
link may be found in a cross-reactivity mechanism (molecular 
mimicry) (30): in fact, the Hp infection may induce the prolifera-
tion of CD4+ T lymphocytes that recognize epitopes of H. pylori 
structurally similar to those of H+/K+ATPase, an enzyme found 
on the apical membrane of parietal cells (31). Indeed, dendritic 
cells may present these shared epitopes to naïve T cells and, in 
the absence of peripheral tolerance, a Th1-driven autoreactive 
clone is activated (28). Again, the cellular immune mechanisms 
of autoimmune thyroiditis show some similarities with those of 
CAG. In HT, inflammation leads to secretion of IFN-γ, a cytokine 
turning thyrocytes into antigen-presenting cells (32). The varia-
tion of costimulatory factors that drive the binding between an 
autoantigen and the T-cell receptor allows the proliferation and 
polarization of autoreactive effector lymphocytes (27). Due to a 
Th17  cell polarization, the inflammatory process and the sub-
sequent fibrosis seem to prevail in the early phase of thyroiditis 
(33); in a later phase, when the lymphocytic infiltration and the 
parenchymal destruction are prevalent, a polarized Th1 profile 
has been reported (34, 35). The Th1 lymphocytes are able to 
aid cytotoxic T-lymphocytes and to produce specific cytokines 
(TNF-α and IFN-γ) able to induce the cellular apoptosis (35) in 
thyroid cells. The association of a gastric autoimmune disorder 
has been shown to add a Th2 cytokine profile to the described 
ones (36). The precise mechanism leading to thyrocytes and/or 
parietal cell death is still unknown. However, the involvement 
of Fas upregulation in thyrocytes, due to IL-1beta produced by 
activated macrophages, has been proven (37). Normal thyro-
cytes, in fact, express FasL but not Fas, while their concomitant 
expression induces an autocrine interaction that may represent 
the main mechanism inducing apoptosis (37). In experimental 
autoimmune gastritis, also parietal cells express Fas that, in this 
case, could trigger apoptosis by binding Fas-ligand on infiltrating 
T cells (28). Following cells damage, the production of specific 
autoantibodies ensues in epiphenomenal fashion (34). Cellular 
and humoral immune cooperation characterizes both autoim-
mune thyroiditis and gastritis leading to the production of 
specific autoantibodies (antithyroperoxidase, antithyroglobulin, 
and antiparietal cell antibodies). These autoantibodies are of 
paramount importance in the diagnosis but of little, if any, in the 
pathogenesis of these autoimmune disorders.
CliniCAl ASPeCTS OF THYROGASTRiC 
SYnDROMe
Clinical pathological aspects of this association are attributable 
to malabsorption of iron and thyroxine, both linked to a reduced 
gastric acid secretion.
iron Deficiency and PA
Chronic atrophic gastritis is clinically silent in most cases 
and only a small percentage of patients may complain about 
dyspeptic symptoms. A well-described clinical feature of 
thyrogastric syndrome is represented by the presence of an 
iron-deficient and/or a PA. In fact, it has been demonstrated 
that an iron-deficient anemia, refractory to oral iron therapy, 
in patients with HT, may be due to chronic atrophic gastritis 
(13). The clinical signs of this disease appear after several years 
of its onset, when the progressive reduction to disappearance 
of the parietal cells leads to atrophy of the gastric mucosa, 
impairing the absorption of iron, vitamin B12 (cobalamin), 
folate, and other nutrients (22). At the physiologic acid pH 
(1.5–2) of the stomach, ascorbic acid, the most active form of 
vitamin C, allows iron reduction from the nutritional ferric (Fe 
+++) to the ferrous form (Fe ++), thus forming a complex that 
drives the absorption in the upper portion of the small intestine 
(22). In the initial phase of the atrophic gastritis, the damage of 
parietal cells can lead to iron deficiency microcytic anemia as 
the only clinical sign (38). When the gastric atrophy becomes 
severe and/or the IFA is no longer produced, even the absorp-
tion of cobalamin becomes compromised. Besides hydrochloric 
acid that promotes the separation of vitamin B12 from food, 
the parietal cells also produce the IFA that binds cobalamin 
and pipes it to the distal ileum, where it is absorbed following 
a binding to specific receptors (39). Vitamin B12 deficiency is 
responsible for hematologic changes (macrocytic anemia) and 
specific neurological disorders (paresthesia and neuritis) which 
are peculiar of PA (22).
Thyroxine Malabsorption in Chronic 
Gastritis
The worldwide used pharmaceutical form of thyroxine (sodium 
levothyroxine, T4) is obtained by native hormone through its 
salification with sodium hydroxide. The absorption of T4 occurs 
in all sections of small intestine being anyway incomplete and 
ranging from 62 to 82% of the ingested dose (40). However, 
increasing evidence of a relevant role of the intact gastric acid 
secretion on the subsequent intestinal absorption of sodium 
levothyroxine has been reported in the last years (41). In fact, 
an increased therapeutic T4 dose has been described in patients 
with gastric disorders (Hp infection, chronic gastritis, gastric 
atrophy) or chronically treated with proton pump inhibitors or 
in non-fasting patients (41–43). All these conditions are char-
acterized by a modified gastric pH that may affect T4 absorp-
tion by changing the ionization status, as already described for 
iron, or the dissolution process of the pharmaceutical T4 form. 
Furthermore, in  vitro studies have shown the pH dependency 
of the dissolution profile of different T4 preparations (44). This 
evidence boosted the research for novel thyroxine formulations 
as liquid or softgel capsules. These ones showed, as compared to 
the classic tablet formulation, a similar or better bioavailability as 
well as a lower number of excipients (45, 46). In clinical studies, 
softgel or liquid formulations performed better in patients with 
gastric disorders (47, 48) and in proton pump inhibitors users 
(49, 50).
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In conclusion, the association of thyroid and gastric autoim-
mune disorders represents a frequent syndrome, included in the 
autoimmune polyendocrine syndrome. The similar or even com-
mon biochemical and pathogenic features fully support the term 
thyrogastric disease described some 60 years ago. From a clinical 
standpoint, the presence of iron-deficient anemia and thyroxine 
malabsorption may represent an alert signal for the presence of 
a gastric disorder in patients with thyroid autoimmunity and 
should trigger a specific diagnostic workup.
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